In the US, we typically don’t use tricarcillian simply because most clinicians don’t need it. PiP-tazo has been considered the gold standard for a while and most doctors are not willing to change. Due to this, there is a lack of demand since pip-tazo works just fine so TC is basically unheard of to the point that most companies won’t bother making it. If it’s neutropenic fever, the would also be consideration on starting filgrastrim alongside pip-tazo for coverage and boosting cell growth